Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (401-410 of 740) with videos related to

Pageof 74
Sort By:
Expert Review of Hematology|March 10, 2020
Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRdAjai Chari, Paul G Richardson, Dorothy Romanus, et al.
American Journal of Hematology|April 10, 2021
Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccineEvangelos Terpos, Ioannis P Trougakos, Filia Apostolakou, et al.
Blood|December 5, 2025
Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myelomaEvangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, et al.
Cancers|June 2, 2021
Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma PatientsKristine A Frerichs, Christie P M Verkleij, Meletios A Dimopoulos, et al.
American Journal of Hematology|January 25, 2024
Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 studyMaria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, et al.
British Journal of Haematology|August 15, 2023
Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab-based therapyFoteini Theodorakakou, Despina Fotiou, Vasiliki Spiliopoulou, et al.
Leukemia|April 25, 2020
Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myelomaHartmut Goldschmidt, Meletios A Dimopoulos, S Vincent Rajkumar, et al.
British Journal of Haematology|November 19, 2014
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasoneGareth Morgan, Antonio Palumbo, Sujith Dhanasiri, et al.
Anticancer Research|August 6, 2005
Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II studyDimosthenis V Skarlos, Haralabos P Kalofonos, George Fountzilas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomesGiovanni Palladini, Angela Dispenzieri, Morie A Gertz, et al.
Pageof 74

Showing results (401-410 of 740) with videos related to

Sort By:
Pageof 74
Expert Review of Hematology|March 10, 2020
Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRdAjai Chari, Paul G Richardson, Dorothy Romanus, et al.
American Journal of Hematology|April 10, 2021
Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccineEvangelos Terpos, Ioannis P Trougakos, Filia Apostolakou, et al.
Blood|December 5, 2025
Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myelomaEvangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, et al.
Cancers|June 2, 2021
Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma PatientsKristine A Frerichs, Christie P M Verkleij, Meletios A Dimopoulos, et al.
American Journal of Hematology|January 25, 2024
Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 studyMaria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, et al.
British Journal of Haematology|August 15, 2023
Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab-based therapyFoteini Theodorakakou, Despina Fotiou, Vasiliki Spiliopoulou, et al.
Leukemia|April 25, 2020
Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myelomaHartmut Goldschmidt, Meletios A Dimopoulos, S Vincent Rajkumar, et al.
British Journal of Haematology|November 19, 2014
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasoneGareth Morgan, Antonio Palumbo, Sujith Dhanasiri, et al.
Anticancer Research|August 6, 2005
Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II studyDimosthenis V Skarlos, Haralabos P Kalofonos, George Fountzilas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomesGiovanni Palladini, Angela Dispenzieri, Morie A Gertz, et al.
Pageof 74